Elekta (OTCMKTS:EKTAY) Shares Gap Up - Here's Why

Key Points

• Elekta shares gapped up — the stock opened at $6.04 versus a prior close of $5.7150, a roughly 5.7% increase, with 5,605 shares changing hands.
• Recent results — Elekta reported $0.09 EPS and $433.29M in revenue for the quarter, with a slightly negative net margin (−0.08%) but positive ROE (12.84%); analysts forecast about $0.36 EPS for the fiscal year.
• Valuation and liquidity — market cap is roughly $2.23B and P/E is deeply negative (−603.4); the company shows modest liquidity (quick ratio 0.73, current ratio 0.95) and debt/equity of 0.56, with 50- and 200-day SMAs at $6.07 and $5.74.

Elekta AB (OTCMKTS:EKTAY - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $5.7150, but opened at $6.04. Elekta shares last traded at $6.04, with a volume of 5,605 shares changing hands.

Elekta Stock Up 5.7%

The company has a market cap of $2.23 billion, a PE ratio of -603.40 and a beta of 1.08. The company has a quick ratio of 0.73, a current ratio of 0.95 and a debt-to-equity ratio of 0.56. The firm's fifty day simple moving average is $6.07 and its 200-day simple moving average is $5.74.

Elekta (OTCMKTS:EKTAY - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.09 earnings per share (EPS) for the quarter. Elekta had a negative net margin of 0.08% and a positive return on equity of 12.84%. The company had revenue of $433.29 million for the quarter. As a group, equities research analysts expect that Elekta AB will post 0.36 earnings per share for the current fiscal year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta's offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company's core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.